Corvidia CEO Davidson Moves to CSO, de Garidel Named Chief Executive

Xconomy Boston — 

Corvidia Therapeutics’ CEO Michael Davidson is taking a new role at the company as its chief scientific officer. Waltham, MA-based Corvidia has appointed Marc de Garidel to succeed Davidson as chief executive. De Garidel’s experience includes six years as chairman and CEO of France-based Ipsen. Corvidia’s lead drug is in a Phase 2 study testing it as a treatment for chronic kidney disease.